We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
AstraZeneca (AZ) and Daiichi Sankyo have announced that an interim analysis from a phase 3 trial showed that their antibody-drug conjugate Enhertu (trastuzumab deruxtecan) posted positive progression-free survival relative to trastuzumab emtansine (T-DM1). Read More
A multidrug chemotherapy cocktail featuring Polivy (polatuzumab vedotin) has scored high as a first-line therapy for patients with diffuse large B-cell lymphoma, (DLBCL), according to preliminary information released by Roche subsidiary Genentech. Read More
In a study of 100 patients who were randomized to receive Nexviazyme or another FDA-approved enzyme replacement therapy, the two treatments showed similar efficacy in improving lung function. Read More
Mechanically ventilated patients with COVID-19 were 44 percent less likely to die when Olumiant (baricitinib) was added to the standard treatment regimen, according to a substudy of Eli Lilly’s COV-BARRIER trial. Read More
The drugmaker projected that a third dose could yield a 100-fold increase in neutralization of the Delta variant when compared against the two-dose regimen. Read More
Axon Neuroscience’s investigational anti-tau antibody treatment for Alzheimer’s disease, AADvac1, has posted positive phase 2b results, reducing cognitive slowing by up to 30 percent and neurodegeneration by 62 percent compared to placebo in patients with biomarker-confirmed disease. Read More